Steel Exchange India receives Andhra Pradesh Maritime Board approval for use of SIMHADRI TMT steel rebars in port projects
Steel Exchange India Limited (SEIL) has received a significant boost after the Andhra Pradesh Maritime Board (APMB) approved the use of its flagship product, SIMHADRI TMT steel rebars, in two major Greenfield port development projects in the state.
According to the company's filing with the stock exchanges, APMB has granted approval for the use of SIMHADRI TMT in the construction of the Greenfield Port at Machilipatnam in Krishna District, a project currently being executed by Megha Engineering & Infrastructures Limited.
In addition, the product has also been approved for use in the construction of the Greenfield Port at Mulapeta in Srikakulam District. This second project is being handled by Vishwa Samudra Ports (JV).
These approvals reflect growing recognition of SEIL's product quality and technical standards, particularly in critical infrastructure developments. As the ports sector continues to expand under India's broader infrastructure drive, such endorsements are likely to enhance SEIL's visibility and future business opportunities.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Krishana Phoschem announces approval for new fertilizer manufacturing plant in Madhya Pradesh
By Aditya Bhagchandani Published on June 19, 2025, 10:54 IST Krishana Phoschem Ltd has announced that its Board of Directors has granted in-principle approval for the establishment of a new fertilizer manufacturing facility in Madhya Pradesh. The announcement was made through an exchange filing dated June 19, 2025. The proposed project will include the setup of a 500 TPD (tons per day) DAP/NPK fertilizer plant and a 300 TPD sulphuric acid plant, or other fertilizer-related manufacturing activities. The facility will be located at Meghnagar in the Jhabua district of Madhya Pradesh. The company plans to fund the project through a combination of internal accruals and debt. The move is expected to enhance Krishana Phoschem's production capacity and support its long-term growth strategy in the agri-inputs segment. This update was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
2 hours ago
- Business Upturn
R Systems shares jump 6% on reports of Coforge considering stake acquisition
Shares of R Systems International rose sharply by over 6% on Wednesday to ₹466.20, following reports that a larger IT company may be considering acquiring a significant stake in the firm. The stock opened stronger and touched an intraday high of ₹468.30, gaining ₹26.70 from its previous close of ₹439.50. The buying interest was sparked by a report from NDTV Profit suggesting that a potential deal involving R Systems is under discussion, though talks are said to be in early stages. While no official announcement has been made, the market reacted positively to speculation of strategic interest in the company. R Systems is a global digital transformation leader providing AI-driven solutions to clients across industries, through a broad range of technology and AI/Analytics services. The company is a leading global provider of technology, artificial intelligence, RPA services and solutions, along with knowledge services. While they do have product engineering capabilities and work with product companies, their main focus is on digital product engineering services—meaning they design and develop software and digital experiences for other companies. Their clientele spans various sectors, including high-tech, telecom, media, finance, and healthcare. At the current market price, R Systems commands a valuation of ₹55.19 billion, with a P/E ratio of 41.03 and a dividend yield of 2.22%. The stock has seen strong momentum in recent weeks, and today's move places it among the top gainers on the NSE. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
4 hours ago
- Business Upturn
Marksans Pharma's UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution
By Aditya Bhagchandani Published on June 19, 2025, 09:14 IST Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the UK's Medicines & Healthcare Products Regulatory Agency (MHRA). The product, used primarily for treating overactive bladder and urinary incontinence, expands Marksans' offering in the urology therapeutic segment and strengthens its European portfolio. The company, headquartered in Mumbai, manufactures and markets generic pharmaceutical formulations globally, with facilities in India, the US, and the UK—approved by regulatory bodies including the USFDA, UKMHRA, and Australia's TGA. 'This approval further reinforces our commitment to expanding our presence in regulated markets through high-quality generic products,' the company said in a press release. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
